Immunizations for FNP Boards: The Complete Schedule, Catch-Up, and Contraindications
Clinical High-Yield · 9 min read · April 28, 2026
Immunization questions are among the most reliably tested content on the FNP boards. They are also among the most learnable — the schedule is fixed, the contraindications are specific, and the boards ask the same types of questions year after year. Here is the complete high-yield guide.
Live vs. Inactivated Vaccines: The Foundational Distinction
Before memorizing the schedule, understand the fundamental distinction that drives most contraindication questions.
Live attenuated vaccines contain weakened but replicating organisms. They produce strong, long-lasting immunity but carry a small risk of causing disease in immunocompromised hosts. Live vaccines: MMR, Varicella (chickenpox), MMRV (ProQuad), Zoster (Zostavax — the older shingles vaccine), LAIV (live attenuated influenza vaccine, the nasal spray), rotavirus, yellow fever, oral typhoid, BCG.
Inactivated vaccines contain killed organisms or protein subunits. They are safe in immunocompromised patients but generally require booster doses. Inactivated vaccines: influenza (injectable), IPV (inactivated polio), hepatitis A, hepatitis B, DTaP/Tdap, Hib, PCV, PPSV23, HPV, meningococcal, zoster (Shingrix — the newer recombinant shingles vaccine), COVID-19 (mRNA and protein subunit).
Board Pearl: The boards love to ask about live vaccine contraindications. Live vaccines are contraindicated in: pregnancy (all live vaccines), severe immunocompromise (HIV with CD4 <200, active chemotherapy, high-dose corticosteroids), and severe combined immunodeficiency (SCID). Inactivated vaccines are safe in all of these populations.
The Adult Immunization Schedule: High-Yield by Vaccine
Influenza: Annual vaccination for all persons ≥6 months. Inactivated influenza vaccine (IIV) is preferred for immunocompromised patients, pregnant women, and adults ≥50 years. LAIV (nasal spray) is an option for healthy non-pregnant adults 2–49 years but is contraindicated in immunocompromised patients, pregnant women, and those with severe asthma or active wheezing.
Tdap/Td: All adults should receive a one-time Tdap (if not previously vaccinated), then Td booster every 10 years. Tdap is recommended during every pregnancy (27–36 weeks gestation) regardless of prior vaccination — this protects the newborn through passive antibody transfer before the infant can be vaccinated.
Pneumococcal vaccines: PCV15 or PCV20 for all adults ≥65 years. If PCV15 is used, follow with PPSV23 at least 1 year later. For immunocompromised adults and those with certain chronic conditions, vaccination is recommended starting at age 19. The boards test that PPSV23 alone is no longer the standard — PCV is now preferred as the initial vaccine.
Zoster (shingles): Recombinant zoster vaccine (Shingrix) is recommended for all immunocompetent adults ≥50 years, given as 2 doses 2–6 months apart. Shingrix is preferred over Zostavax (which is no longer available in the US). Shingrix is also recommended for adults who previously received Zostavax. Key point: Shingrix is an inactivated (recombinant) vaccine — it is safe in immunocompromised patients (though immunogenicity may be reduced).
HPV: Recommended for all persons through age 26 years. Shared clinical decision-making for ages 27–45 (some benefit, but most adults in this age group have already been exposed). 2-dose series if started before age 15; 3-dose series if started at age 15 or older, or if immunocompromised.
Hepatitis A: 2-dose series for all adults who are not immune. Recommended for travelers to endemic areas, men who have sex with men, people with chronic liver disease, people who use injection drugs, and those with direct contact with hepatitis A-infected persons.
Hepatitis B: 3-dose series for all unvaccinated adults. A 2-dose series (Heplisav-B) is available for adults ≥18 years. Recommended for all adults through age 59; shared clinical decision-making for adults ≥60 years.
Meningococcal: MenACWY for all adolescents at 11–12 years (booster at 16 years). Also recommended for college freshmen living in dormitories, military recruits, asplenic patients, and travelers to endemic areas. MenB (serogroup B meningococcal vaccine) is recommended for high-risk groups and is an option for adolescents 16–23 years (shared clinical decision-making).
Special Populations: Immunocompromised, Pregnant, and Asplenic
Immunocompromised patients: Avoid all live vaccines. Inactivated vaccines are safe but may have reduced immunogenicity. HIV-positive patients with CD4 ≥200 can receive MMR and Varicella. All HIV-positive patients should receive annual influenza (IIV), pneumococcal, hepatitis A, hepatitis B, and Tdap vaccines.
Pregnant women: Avoid all live vaccines (MMR, Varicella, LAIV). Recommended during pregnancy: Tdap (27–36 weeks every pregnancy), annual influenza (IIV), COVID-19, RSV (if 32–36 weeks during RSV season). Hepatitis A, hepatitis B, and meningococcal vaccines can be given if indicated.
Asplenic patients (functional or anatomic): At highest risk for encapsulated organisms — Streptococcus pneumoniae, Haemophilus influenzae type b, Neisseria meningitidis. Ensure vaccination with PCV20 (or PCV15 + PPSV23), Hib, MenACWY, and MenB. Vaccinate at least 2 weeks before elective splenectomy if possible.
Catch-Up Vaccination: The Key Principles
The boards test catch-up vaccination for adults who missed vaccines in childhood. Key principles:
MMR: Adults born before 1957 are considered immune to measles and mumps (presumed exposure). Adults born in 1957 or later without evidence of immunity should receive at least 1 dose of MMR (2 doses for healthcare workers, students, and international travelers).
Varicella: Adults without evidence of immunity should receive 2 doses of varicella vaccine 4–8 weeks apart. Evidence of immunity: documentation of 2 doses of vaccine, laboratory evidence of immunity, or healthcare provider diagnosis of chickenpox.
Hepatitis B: The 3-dose series can be given at any age. A 2-dose Heplisav-B series is available for adults ≥18 years.
Minimum intervals: The boards test that vaccines given too close together may not be valid. Live vaccines given on the same day are acceptable, but if not given on the same day, they must be separated by at least 28 days (4 weeks).
The Bottom Line
Immunization questions on the FNP boards reward knowing the schedule, the contraindications, and the special population recommendations. Live vaccines are contraindicated in pregnancy and severe immunocompromise. Tdap is given every pregnancy. Shingrix is preferred over Zostavax. Asplenic patients need pneumococcal, Hib, and meningococcal vaccines. Master these and immunizations becomes one of your most reliable point-earners on the exam.
→ Explore the FNP Board Review Book — every immunization topic covered with board-focused clinical pearls and practice questions.